We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers' Idhifa Fails to Meet Goal in Leukemia Study
Read MoreHide Full Article
Bristol Myers Squibb (BMY - Free Report) announced that the phase III IDHENTIFY study evaluating Idhifa in patients with relapsed or refractory acute myeloid leukemia (R/R AML) did not meet the primary endpointof overall survival. AML is one of the most difficult-to-treat blood cancers
Shares of the company have declined 2.3% year to date against the industry’s growth of 1.6%.
The IDHENTIFY study was evaluating the efficacy and safety of Idhifa plus best supportive care versus conventional care regimens in subjects 60 years or older with AML refractory to or relapsed after second- or third-line AML therapy with an IDH2 mutation. The conventional care regimens included continuous 28-day cycles of best supportive care (BSC) only —Vidaza (made by Bristol-Myers’ subsidiary Celgene) plus BSC, low-dose cytarabine plus BSC or intermediate-dose cytarabine plus BSC. Results showed no statistically significant improvement in OS among patients in the Idhifa+BSC arm.
The company will present detailed results from the study at a future medical meeting.
We remind investors that Idhifa is approved by the FDA for the treatment of adult patients with relapsed or refractory AML with an IDH2 mutation as detected by an FDA-approved test.
The company also markets anotherleukemia drug, Sprycel, contributing significantly to the top line. Sprycel is used in adults and children to treat a type of blood cancer called Philadelphia chromosome-positive chronic myelogenous leukemia (CML). The drug is also used to treat Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) in adults and children.
The company is looking to counter generic threat for its key drugs through deals and acquisitions, and by introducing new products to augment its product portfolio. Very recently, Bristol Myers announced a definitive agreement with privately-held, clinical-stage biopharmaceutical company, Forbius, for TGF-beta assets.
Zacks Rank and Stocks to Consider
Currently, Bristol Myers is a Zacks Rank #3 (Hold) stock.
Some better-ranked stocks in the healthcare sector include Emergent Biosolutions Inc. (EBS - Free Report) , Horizon Therapeutics Public Limited Company and Alimera Sciences Inc. (ALIM - Free Report) . While Emergent and Horizon Therapeutics sport a Zacks Rank #1 (Strong Buy), Alimera carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Emergent’s earnings estimates have increased from $3.45 to $5.60 for 2020 and from $3.73 to $6.67 for 2021 over the past 60 days.
Horizon Therapeutics’ earnings estimates have increased from $1.77 to $2.86 for 2020 and from $2.72 to $4.29 for 2021 over the past 60 days.
Alimera’s loss per share estimates have narrowed from $2.33 to $1.31 for 2020 and from 63 cents to 52 cents for 2021 over the past 60 days.
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, SherazMian hand-picks one to have the most explosive upside of all. With users in 180 countries and soaring revenues, it’s set to thrive on remote working long after the pandemic ends. No wonder it recently offered a stunning $600 million stock buy-back plan. The sky’s the limit for this emerging tech giant. And the earlier you get in, the greater your potential gain.
Image: Bigstock
Bristol Myers' Idhifa Fails to Meet Goal in Leukemia Study
Bristol Myers Squibb (BMY - Free Report) announced that the phase III IDHENTIFY study evaluating Idhifa in patients with relapsed or refractory acute myeloid leukemia (R/R AML) did not meet the primary endpointof overall survival. AML is one of the most difficult-to-treat blood cancers
Shares of the company have declined 2.3% year to date against the industry’s growth of 1.6%.
The IDHENTIFY study was evaluating the efficacy and safety of Idhifa plus best supportive care versus conventional care regimens in subjects 60 years or older with AML refractory to or relapsed after second- or third-line AML therapy with an IDH2 mutation. The conventional care regimens included continuous 28-day cycles of best supportive care (BSC) only —Vidaza (made by Bristol-Myers’ subsidiary Celgene) plus BSC, low-dose cytarabine plus BSC or intermediate-dose cytarabine plus BSC. Results showed no statistically significant improvement in OS among patients in the Idhifa+BSC arm.
The company will present detailed results from the study at a future medical meeting.
We remind investors that Idhifa is approved by the FDA for the treatment of adult patients with relapsed or refractory AML with an IDH2 mutation as detected by an FDA-approved test.
The company also markets anotherleukemia drug, Sprycel, contributing significantly to the top line. Sprycel is used in adults and children to treat a type of blood cancer called Philadelphia chromosome-positive chronic myelogenous leukemia (CML). The drug is also used to treat Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) in adults and children.
The company is looking to counter generic threat for its key drugs through deals and acquisitions, and by introducing new products to augment its product portfolio. Very recently, Bristol Myers announced a definitive agreement with privately-held, clinical-stage biopharmaceutical company, Forbius, for TGF-beta assets.
Zacks Rank and Stocks to Consider
Currently, Bristol Myers is a Zacks Rank #3 (Hold) stock.
Some better-ranked stocks in the healthcare sector include Emergent Biosolutions Inc. (EBS - Free Report) , Horizon Therapeutics Public Limited Company and Alimera Sciences Inc. (ALIM - Free Report) . While Emergent and Horizon Therapeutics sport a Zacks Rank #1 (Strong Buy), Alimera carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Emergent’s earnings estimates have increased from $3.45 to $5.60 for 2020 and from $3.73 to $6.67 for 2021 over the past 60 days.
Horizon Therapeutics’ earnings estimates have increased from $1.77 to $2.86 for 2020 and from $2.72 to $4.29 for 2021 over the past 60 days.
Alimera’s loss per share estimates have narrowed from $2.33 to $1.31 for 2020 and from 63 cents to 52 cents for 2021 over the past 60 days.
Bristol Myers Squibb Company Price
Bristol Myers Squibb Company price | Bristol Myers Squibb Company Quote
Zacks’ Single Best Pick to Double
From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, SherazMian hand-picks one to have the most explosive upside of all. With users in 180 countries and soaring revenues, it’s set to thrive on remote working long after the pandemic ends. No wonder it recently offered a stunning $600 million stock buy-back plan. The sky’s the limit for this emerging tech giant. And the earlier you get in, the greater your potential gain.
Click Here, See It Free >>